BRPI0606323A2 - identificação0 de fosfolipase a2 como alvo no tratamento de cáncer, com ênfase especial no cáncer colorretal e seu mecanismo de ação - Google Patents
identificação0 de fosfolipase a2 como alvo no tratamento de cáncer, com ênfase especial no cáncer colorretal e seu mecanismo de açãoInfo
- Publication number
- BRPI0606323A2 BRPI0606323A2 BRPI0606323-3A BRPI0606323A BRPI0606323A2 BR PI0606323 A2 BRPI0606323 A2 BR PI0606323A2 BR PI0606323 A BRPI0606323 A BR PI0606323A BR PI0606323 A2 BRPI0606323 A2 BR PI0606323A2
- Authority
- BR
- Brazil
- Prior art keywords
- phospholipase
- cancer
- identification
- target
- gene expression
- Prior art date
Links
- 102100037611 Lysophospholipase Human genes 0.000 title abstract 5
- 108010058864 Phospholipases A2 Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 206010009944 Colon cancer Diseases 0.000 title abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 2
- 230000010534 mechanism of action Effects 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 abstract 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 abstract 1
- 230000004709 cell invasion Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 230000014493 regulation of gene expression Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01004—Phospholipase A2 (3.1.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
IDENTIFICAçãO DE FOSFOLIPASE A2 COMO ALVO NO TRATAMENTO DE CáNCER, COM êNFASE ESPECIAL NO CáNCER COLORRETAL E SEU MECANISMO DE AçãO. A presente invenção refere-se a um peptídeo de fosfolipase A2 que foi detectado em plasma ser humano e sintetizado, O peptídeo foi injetado nos camundongos e a determinação de perfil de expressão de gene sobre muitos órgáos foi realizada. A fosfolipase A2 mostrou efeitos significativos sobre a regulação de expressão de gene no fígado. Os genes afetados são elementos da via de sinalização de integrina, via wnt e via PTEN. As alterações em expressão de gene indicam um efeito positivo de fosfolipase A2 sobre a proliferação e invasão celular. A anotação de gene aponta para câncer colorretal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64399005P | 2005-01-14 | 2005-01-14 | |
| PCT/US2006/000953 WO2006076414A2 (en) | 2005-01-14 | 2006-01-12 | Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606323A2 true BRPI0606323A2 (pt) | 2009-06-16 |
Family
ID=36678156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606323-3A BRPI0606323A2 (pt) | 2005-01-14 | 2006-01-12 | identificação0 de fosfolipase a2 como alvo no tratamento de cáncer, com ênfase especial no cáncer colorretal e seu mecanismo de ação |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070298022A1 (pt) |
| EP (1) | EP1843784A2 (pt) |
| JP (1) | JP2008526971A (pt) |
| KR (1) | KR20070094785A (pt) |
| CN (1) | CN101102790A (pt) |
| AU (1) | AU2006204988A1 (pt) |
| BR (1) | BRPI0606323A2 (pt) |
| CA (1) | CA2593541A1 (pt) |
| MX (1) | MX2007008559A (pt) |
| RU (1) | RU2007130799A (pt) |
| WO (1) | WO2006076414A2 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9657109B2 (en) | 2012-11-02 | 2017-05-23 | Wisconsin Alumni Research Foundation | Compositions and methods for the treatment of systemic inflammatory response syndromes |
| CN105561301B (zh) * | 2016-01-21 | 2020-04-10 | 中山大学 | 华支睾吸虫分泌型磷脂酶a2蛋白在制备肿瘤治疗药物中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812017B2 (en) * | 2000-10-11 | 2004-11-02 | Centre National De La Recherche Scientique - Cnrs | Mammalian secreted group IIF phospholipase A2 |
| EP1578940A4 (en) * | 2002-11-13 | 2007-12-12 | Genentech Inc | METHOD AND COMPOSITIONS FOR DYSPLASED DIAGNOSIS |
-
2006
- 2006-01-12 CA CA002593541A patent/CA2593541A1/en not_active Abandoned
- 2006-01-12 BR BRPI0606323-3A patent/BRPI0606323A2/pt not_active IP Right Cessation
- 2006-01-12 RU RU2007130799/15A patent/RU2007130799A/ru not_active Application Discontinuation
- 2006-01-12 KR KR1020077016174A patent/KR20070094785A/ko not_active Application Discontinuation
- 2006-01-12 EP EP06718068A patent/EP1843784A2/en not_active Withdrawn
- 2006-01-12 CN CNA2006800024071A patent/CN101102790A/zh active Pending
- 2006-01-12 US US11/813,619 patent/US20070298022A1/en not_active Abandoned
- 2006-01-12 JP JP2007551341A patent/JP2008526971A/ja active Pending
- 2006-01-12 AU AU2006204988A patent/AU2006204988A1/en not_active Abandoned
- 2006-01-12 WO PCT/US2006/000953 patent/WO2006076414A2/en active Application Filing
- 2006-01-12 MX MX2007008559A patent/MX2007008559A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2593541A1 (en) | 2006-07-20 |
| US20070298022A1 (en) | 2007-12-27 |
| KR20070094785A (ko) | 2007-09-21 |
| WO2006076414A2 (en) | 2006-07-20 |
| WO2006076414A3 (en) | 2007-03-22 |
| JP2008526971A (ja) | 2008-07-24 |
| EP1843784A2 (en) | 2007-10-17 |
| AU2006204988A1 (en) | 2006-07-20 |
| CN101102790A (zh) | 2008-01-09 |
| RU2007130799A (ru) | 2009-02-20 |
| MX2007008559A (es) | 2007-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125263T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
| WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| EP3722810A3 (en) | Molecular profiling of tumors | |
| BR112013000822A2 (pt) | método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais | |
| CY1119854T1 (el) | Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου | |
| BR112012027143A2 (pt) | enzima da doença do armazenamento lisossomal | |
| WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| WO2010055487A3 (en) | Compositions and methods for micro-rna expession profiling of colorectal cancer | |
| WO2009006577A3 (en) | Compositions and methods for inhibiting ezh2 | |
| BR122018069446B8 (pt) | método in vitro para detectar a presença de um célula de câncer em um indivíduo | |
| WO2010055488A3 (en) | Compositions and methods for micro-rna expession profiling of hepatocellular cancer | |
| WO2012061683A3 (en) | Methods for treating cancer | |
| BR112016029781A2 (pt) | composições e métodos para inibir a expressão de gene de alfa-1 antitripsina | |
| BR112017025698A2 (pt) | composições e métodos para inibir a expressão do gene de hif2alfa | |
| WO2011056688A3 (en) | Molecular profiling for personalized medicine | |
| BR112014026801A2 (pt) | 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazina-2-carbonitrila e usos terapêuticos do mesmo | |
| WO2007098611A8 (en) | Compositions for treatment of cancer | |
| WO2008073878A3 (en) | Gene expression profiling of esophageal carcinomas | |
| WO2009026128A3 (en) | Gene expression markers of recurrence risk in cancer patients after chemotherapy | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| AR080891A1 (es) | Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores | |
| BRPI1014978A2 (pt) | método de tratamento do câncer e composição farmacêutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |